Automate Your Wheel Strategy on TYRA
With Tiblio's Option Bot, you can configure your own wheel strategy including TYRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TYRA
- Rev/Share 0.0083
- Book/Share 5.0738
- PB 2.306
- Debt/Equity 0.0199
- CurrentRatio 21.943
- ROIC -0.3947
- MktCap 622831880.0
- FreeCF/Share -1.4564
- PFCF -7.1814
- PE -6.5835
- Debt/Assets 0.0187
- DivYield 0
- ROE -0.318
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | TYRA | Piper Sandler | -- | Overweight | -- | $33 | May 21, 2025 |
| Initiation | TYRA | UBS | -- | Buy | -- | $28 | Jan. 7, 2025 |
| Upgrade | TYRA | BofA Securities | Neutral | Buy | $22 | $31 | Oct. 18, 2024 |
News
Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
TYRA
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Tyra Biosciences (TYRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
About Tyra Biosciences, Inc. (TYRA)
- IPO Date 2021-09-15
- Website https://www.tyra.bio
- Industry Biotechnology
- CEO Todd Harris
- Employees 60
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.